Chronic Myelogenous Leukemia: Biology and Therapy
Authors:
- 3 August 1999
- journal article
- review article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 131 (3) , 207-219
Abstract
Chronic myelogenous leukemia is a myeloproliferative disorder. It is characterized by a biphasic or triphasic clinical course in which a benign chronic phase is followed by transformation into an accelerated and blastic phase. On a cytogenetic and molecular level, most patients with chronic myelogenous leukemia demonstrate BCR-ABL fusion genes in hematopoietic progenitor cells, which result from a reciprocal translocation between chromosomes 9 and 22; this translocation leads to a shortened chromosome 22, called the Philadelphia chromosome. Translation of the fusion products yields chimeric proteins of variable size that have increased tyrosinekinase activity. Conventional chemotherapy with hydroxyurea or busulfan can achieve hematologic control but cannot modify the natural disease course, which inevitably terminates in a rapidly fatal blastic phase. Since its introduction in the 1980s, allogeneic stem-cell transplantation has provided the groundwork for a cure of chronic myelogenous leukemia. However, few patients are eligible for this treatment because of donor availability and age restrictions. Therapy with interferon-α alone or in combination with cytarabine suppresses theleukemic clone, produces cytogenetic remissions, and prolongs survival. It is an effective alternative first-line treatment for patients ineligible for transplantation. New drugs active against chronic myelogenous leukemia may show increased activity in the transformed phases of the disease. Novel therapies and concepts are developing rapidly; targeted molecules are tyrosine kinases, ras, and messenger RNA through antisense oligonucleotides. Alternative transplantation options, such as stem cells from autologous sources and matched unrelated donors, are expanding. Immunomodulation by adoptive immunotherapy and vaccine strategies hold significant promise for the cure of chronic myelogenous leukemia.Keywords
This publication has 109 references indexed in Scilit:
- Bone Marrow Transplants from Unrelated Donors for Patients with Chronic Myeloid LeukemiaNew England Journal of Medicine, 1998
- Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationBone Marrow Transplantation, 1997
- European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matchingBone Marrow Transplantation, 1997
- Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cellsHuman Immunology, 1997
- Hydroxyurea dermopathy: A unique lichenoid eruption complicating long-term therapy with hydroxyureaJournal of the American Academy of Dermatology, 1997
- Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16‐year periodBritish Journal of Haematology, 1997
- Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.Journal of Clinical Investigation, 1994
- The Molecular Genetics of Philadelphia Chromosome–Positive LeukemiasNew England Journal of Medicine, 1988
- Cancer Incidence and Survival in Patients 65 Years of Age and OlderCA: A Cancer Journal for Clinicians, 1986
- Population‐Based Age‐ and Sex‐Specific Incidence Rates in the 4 Main Types of LeukaemiaScandinavian Journal of Haematology, 1982